ABL Diagnostics
9BK0
Company Profile
Business description
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
Contact
72c, rue de, WOIPPY
Thionville57140
FRAT: +33 783646850
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
stocks
Cheap ASX energy play boasts strong cash flows and balance sheet
Markets appear overly bearish on the company despite the company having attracting growth options.
stocks
Market overreacts to earnings miss from moated ASX retailer
Our forecast recovery is off to a slow start but the sell-off appears to have gone too far.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,207.30 | 32.70 | -0.35% |
| CAC 40 | 7,725.70 | 117.34 | -1.50% |
| DAX 40 | 24,184.63 | 88.49 | -0.36% |
| Dow JONES (US) | 45,282.47 | 349.27 | -0.77% |
| FTSE 100 | 9,268.73 | 52.67 | -0.57% |
| HKSE | 25,524.92 | 304.99 | -1.18% |
| NASDAQ | 21,449.29 | 47.24 | -0.22% |
| Nikkei 225 | 42,394.40 | 413.42 | -0.97% |
| NZX 50 Index | 12,957.98 | 121.52 | -0.93% |
| S&P 500 | 6,439.32 | 27.59 | -0.43% |
| S&P/ASX 200 | 8,935.60 | 31.30 | -0.35% |
| SSE Composite Index | 3,868.38 | 15.18 | -0.39% |